BOT 2.27% 22.5¢ botanix pharmaceuticals ltd

"Without some sign of efficacy in the US population cohort the...

  1. 34,304 Posts.
    lightbulb Created with Sketch. 8997
    "Without some sign of efficacy in the US population cohort the FDA is not going to give its approval to continue to Phase III."
    That's a big statement.

    MD said, the company currently has around $37m cash, presumably not including $7m research refund, then $44m, but still need to raise more cash for Phase III if go ahead.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
0.005(2.27%)
Mkt cap ! $354.4M
Open High Low Value Volume
22.5¢ 24.0¢ 22.0¢ $2.251M 9.851M

Buyers (Bids)

No. Vol. Price($)
5 350473 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 140208 4
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
22.5¢
  Change
0.005 ( 2.27 %)
Open High Low Volume
22.5¢ 24.0¢ 22.0¢ 4728143
Last updated 15.58pm 29/03/2024 ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.